Events

7th Annual Cell & Gene Therapy Innovation Summit

February 8, 2024
 

Presentation.

Selecta Biosciences and Cartesian Therapeutics Merger Conference Call

November 13, 2023 at 9:00a E.T.
 

Click here for webcast.

Presentation.

FOCIS Annual Meeting

June 20-23, 2023.  Boston, Massachusetts
 

June 20, 15:00 ET – Dr. Jewell delivers an invited presentation with highlights from his career designing innovative technologies to advance immunotherapies for cancer and autoimmunity that are safe and long lasting. This includes selected examples spanning biomaterials, nanotechnology, RNA-engineering, and cell therapy. 

Gene Therapy Development and Manufacturing Conference

June 13-14, 2023.  London, UK

June 14 10:30 ET – Dr. Christopher Jewell, Chief Scientific Officer, gives a talk titled” RNA Cell Therapy For Autoimmune Diseases and Cancer” virtually. Dr. Jewell discusses rCAR-T in myasthenia gravis and other autoimmune diseases and manufacturing of autologous RNA cell therapies. 

mRNA Quality Control & Comparability Summit 2023

June 13-18, 2023.  Boston, Massachusetts

June 14 09:00 AM ET – Dr. Emily English, VP of Quality, gives a talk titled “Maximizing the Stability of Your mRNA Products to Ensure Patients Safety & Efficacy”. Dr. English discusses strategies to substitute nucleotides at the mRNA synthesis stage to bolster the stability of mRNA, the mechanism behind synthetic ‘anti-reverse cap analogs’ for increased mRNA therapeutics stability, and the benefits of modifying the chemical structure of the mRNA cap to increase stability.

Inside Precision Medicine

June 7, 2023 – Dr. Christopher Jewell, Chief Scientific Officer, discusses the challenges in developing cell and gene therapies in Inside Precision Medicine’s latest article.

June 1, 2023 – Cartesian Therapeutics hosts the MD Tech Council and U.S-Egypt Science and Technology Joint Fund to discuss commercialization of academic discoveries.

UMBC Mic’d Up

May 18, 2023 – Dr. Miloš Miljković, Chief Medical Officer, discusses the irreplaceable nature of clinical trials, demystifying why there really is no alternative to conducting clinical trials and how these trials form the bedrock of evidence-based medicine on the UMBC Mic’d up Podcast with Dennise Cardona.

16th Nano-Bio Symposium on Cell Programming

April 21, 2023.  John Hopkins Homewood Campus in Maryland

April 21, 10 a.m. ET – Dr. Chris Jewell, Chief Scientific Officer, delivers talk at the Cell Programming Symposium held at the Center for NanoBioTechnology at Johns Hopkins University. In a talk titled “Engineering Next Generation Cell Therapies with RNA CARs”, Dr. Jewell discussed the potential of RNA-based cell therapies and the work Cartesian is doing to advance this exciting field in cancer and autoimmune therapy.

April 21, 11:30 a.m. ET – Dr. Murat Kalayoglu, Chief Executive Officer participates in a panel discussion with other key opinion leaders to discuss “Challenges in Translating Cell Therapies”.

Boğaziçi LifeSci Symposium: Targeted Therapy Technologies

April 3-4, 2023.  Istanbul, Turkey

April 3, 8:30 AM ET – Metin Kurtoglu, Chief Operating Officer gives a virtual talk titled “Utilizing RNA Engineering for Advancing Cell Therapy in Autoimmune Conditions”. Dr. Kurtoglu discusses the ongoing trial for Myasthenia Gravis and the potential for RNA cell therapy for other autoimmune disorders.

RNA Leaders Europe Congress

March 15-16, 2023.  Basel, Switzerland

Mar 15, 9:55 AM ET – Emily English, VP of Quality will give a presentation titled “Utilizing RNA Engineering For Advancing Cell Therapy In Autoimmune Conditions”.  Dr. English will discuss the technology and its applications, review major challenges in advancing cell programs, and share early clinical data for autoimmune conditions.

Advanced Therapies Congress 2023

Mar 15, 2023.  London, UK

Dr. Andrew Stewart, VP – Research, gives talk entitled “RNA CAR T cell Therapy of Autoimmune Disease”, discussing the specific advantages that RNA CAR T therapy can provide for treatment of autoimmunity. 

6th CAR-TCR Summit Europe

Feb 23, 2023,. London, UK

Dr. Andrew Stewart, VP – Research, gives talk entitled “Towards the First CAR-T Cell Therapy for Autoimmune Disease”, reviewing progress in development of Descartes-08 for generalized Myasthenia Gravis, followed by participation in a panel discussion on “Exploring the Opportunities for Cell Therapies to Treat Indications Beyond Oncology”.

2nd Annual mRNA-Based Therapeutics Summit Europe

January 24-26, 2023, Hotel Palace Berlin in Germany

January 25, 7 a.m. ET-Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Revealing the Lasted Advances in Novel mNRA Delivery Systems for LNPs & Beyond to Expand the Therapeutic Applicability of mRNA-Based Therapeutics Panel Discussion. Dr. Kurtoglu will discuss harnessing the power of biophysical modeling to improve mRNA delivery of the future and standardizing mRNA delivery systems for various disease treatment.

January 25, 8 a.m. ET-Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Optimizing Manufacturing Strategies for mRNA Vaccines & Therapeutics session and will lead a presentation titled “Building Robust Quality Systems in a Cell Therapy Company”. Dr. Kurtoglu will discuss transitioniing from discovery science to manufacturing for clinical programs, how to build a quality organization from scratch and developing risk-based, scientifically informed quality systems.

RNA Cell Therapies Summit

January 24-26, 2023, Embassy Suites, Boston Logan Airport in Massachusetts

January 25, 1:30 p.m. ET-Dr. Emily English, Senior Director, Quality, participates in the Optimizing Cell & RNA Characterization to Streamline Analytical Assessments session. Dr. English will lead a presentation titled “Leveraging Efficient Analytical Techniques to Meet Quality Attributes Rapidly & Meet Regulatory Expectations in RNA Cell Therapy”. Dr. English will define key quality attributes for RNA cell therapy and modifications and manufacturing methodologies to improve long-term purity of RNA to prevent expression of off-target receptors.

January 25, 2 p.m. ET-Dr. Milos Miljkovic will participate in the Demonstrating Safety & Toxicity to Accelerate Through Clinical Investigations session. Dr. Miljkovic will lead a presentation titled “Accelerating RNA Cell Therapeutics Development from Bench to Bedside (& Back) for Use in Oncology & Beyond”. Dr. Miljkovic will discuss optimal pathways to the clinical for RNA cell therapeutics and cGMP considerations to assess before embarking on clinical development, assess best ways to measure pharmacokinetics and pharmacodynamics properties of RNA cell therapeutics, and highlight unique safety and toxicology considerations for this class of drugs.

11th Annual CT3N Symposium

December 7, 2022, Biomedical Research Building at the University of Pennsylvania in Philadelphia

December 7, 11:55 a.m. ET-Dr. Michael Singer, Chief Scientific Officer, discusses RNA engineered cell therapies for treatment of autoimmune diseases in his talk titled “Engineering Biological Carriers for Targeted Delivery of Therapeutics”.

Cell and Gene Therapy Manufacturing and Commercialization Europe Conference

December 4-7, 2022, Convention Centre Dublin in Ireland

December 7, 2:00 PM CET/CEST-Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Next Generation Non-Viral Gene Editing for Smarter Cell and Gene Therapies Panel Discussion. Dr. Kurtoglu will discuss how RNA cell therapy is transforming the cell therapy field for both autologous and allogenic products.

Cell and Gene Therapy Manufacturing and Commercialization Europe Conference

December 4-7, 2022, Convention Centre Dublin in Ireland

December 6, 2:30 PM CET/CEST-Dr. Emily English, Senior Director, Quality, participates in the Gene Edited Ex Vivo Cell Therapy Manufacturing session. Dr. English will discuss the attributes and advantages of RNA cell therapy that rise to unique considerations for product quality.

MGFA’s What’s New in MG Research Webinar

November 29, 2022, Virtual

November 29, 3 p.m. ET-Dr. Milos Miljkovic, Chief Medical Officer, discusses the latest results from the Descartes-08 clinical trial, which is investigating the effectiveness of RNA CAR T-cell therapy for generalized Myasthenia Gravis and plans for further development of Descartes-08 for other autoimmune diseases.

MGFA Community Health Fair

November 12, 2022, St. Petersburg Marriott Clearwater in Florida

November 12, 2 p.m. ET—Cartesian participates in MGFA’s Community Health Fair to connect, learn and share more about Descartes-08, the first CAR T-cell therapy for autoimmune disease with the MG community.

MGFA Community Health Fair

November 6, 2022, Georgia Tech Institute Exhibition Hall in Georgia

November 6, 10 a.m. ET—Cartesian participates in MGFA’s Community Health Fair to connect, learn and share more about Descartes-08, the first CAR T-cell therapy for autoimmune disease with the MG community.

Maryland Life Sciences Bio Innovation Conference

October 3-4, 2022, Bethesda Country Club

October 3, 10:00 a.m. ET-Dr. Milos Miljkovic, Chief Medical Officer, participates in the Expanding the Boundaries of Cell and Gene Therapy session. Dr. Miljkovic will discuss expanding boundaries to create new generation of therapies that will enhance patient outcomes

7th Annual CAR-TCR Summit

September 19-21, 2022, Hynes Convention Center in Boston

September 21, 2:00 p.m. ET-Dr. Michael Singer, Chief Scientific Officer, participates in the Leveraging RNA Technology to Change the Face of Clinical Trial Design session. Dr. Singer will discuss how they can be used as treatments beyond oncology due to their predictable pharmacokinetics and enhanced safety.

September 21, 3:00 p.m. ET- Dr. Michael Singer, Chief Scientific Officer, participates in the Innovating the Future of Cell Therapy with RNA-Based Approaches panel discussion.

AANEM Annual Meeting

September 21-24, 2022, Gaylord Opryland Resort & Convention Center in Nashville

September 21, 9:44 a.m. CT-Dr. Volkan Granit, participates in the MGFA session to present data from the phase 2a clinical trial of Descartes-08 in a talk titled ”Phase 1/2A Study of Descartes-08, Autologous mRNA-Engineered Chimeric Antigen Receptor T cells in gMG”.

7th Annual CAR-TCR Summit

September 19-21, 2022, Hynes Convention Center in Boston

September 19, 9:30 a.m. ET- Dr. Milos Miljkovic, Chief Medical Officer, participates in the Innovations in Gene Engineering & Editing session. Dr. Miljkovic will discuss he pros, cons and applications of key gene editing technologies that are making RNA editing a reality in cell therapy.

September 19, 1:30 p.m. ET- Dr Milos Miljkovic, Chief Medical Officer, participates in the Exploring the Advantages & Applications of CAR-T Technology Beyond Oncology workshop to discuss non-oncology indications of CAR-T and how Cartesian has successfully utilized CAR-T therapy for an ongoing Phase 2 clinical trial for Myasthenia Gravis.

mRNA Processing Development & Manufacturing Summit

September 20-22, 2022, Hilton Boston

September 20, 9:00 a.m. ET

Emily English, Senior Director, Quality, participates in the “Defining mRNA Drug Substance Quality Control Attributes” worship. Dr. English will discuss the strategies and methods for mRNA quality control and provide a better understanding of quality requirements for process monitoring and lot release of mRNA-based therapeutic products. 

July 26-28, 2022, Hilton Boston

July 28, 12:00 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Unleashing the Power of mRNA Technology for CAR-T Therapies session, a presentation titled “Cell Therapy: In & Beyond Oncology.” Dr. Kurtoglu will discuss cell products engineered with RNA that express Chimeric Antigen Receptor (CAR) being tested in autoimmune disease and frontline oncology indications and the potential of RNA Cell Therapies as there is no limit to the number of cells that can be transfected with multiple RNAs and therapeutic functions.

July 28, 4:25 p.m. ET – Dr. Milos Miljkovic, Chief Medical Officer, participates in the Achieving a Successful Route to Equitable Distribution for mRNA-Based Therapeutics & Vaccines session and will lead a presentation titled “Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering.” Dr. Miljkovic will focus on the advantages of RNA-engineered cellular therapy over DNA-based cell therapy. He will also discuss how Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the U.S., and the potential of RNA to make global distribution of effective clinical therapies more equitable.

June 15-18, 2022, Moscone West Convention Center in San Francisco

June 15, 8:30 a.m. PT / 11:30 a.m. ET (available on the virtual meeting platform) – Dr. Murat Kalayoglu, President and Chief Executive Officer, participates as a panelist in Maryland Stem Cell Research Fund Focus Session, “Accelerating Cures – Translating Stem Cell Discoveries into Therapies.” In this Focus session, Maryland-based leaders in the field explore the latest breakthroughs and advances in stem cell disease modeling and tissue engineering approaches. Hear from Dr. Kalayoglu on creating, manufacturing and delivering cell therapies to patients with unmet medical needs.

June 9, 2022, Postillion Hotel Amsterdam; Digital Experience: All Sessions Livestreamed June 7 – 9

June 9, 2022, 16:55 CET (10:55 a.m. ET) – Dr. Michael Singer presents at Informa’s Antibody Engineering & Therapeutics Conference in a session titled “RNA-Engineered Cell Therapies for Autoimmune Disease.” RNA cell therapies combine the potency of DNA-engineering (such as CAR T-cells) with the speed and manufacturability of RNA. RNA offers another key advantage: controllable pharmacokinetics. In our clinical trials, RNA cell therapies have been remarkably safe. We have administered them in outpatient clinics, with no need for preconditioning chemotherapy. This benefit:risk profile has allowed us to develop therapies for autoimmune disease, including Descartes-08, an anti-BCMA CAR T-cell, for autoantibody-mediated diseases like myasthenia gravis.

May 12, 2022, Bethesda North Marriott Hotel & Conference Center

May 12, 5:30 p.m. ET – Cartesian has been selected as a finalist for the Emerging Life Sciences Company of the Year award for the Maryland Tech Council’s Industry Awards Celebration. The Industry Awards Celebration hosts attendees from the life sciences and technology industries and is Maryland’s largest and most prestigious award ceremony of its kind.

May 10-12, 2022, Hyatt Regency Miami

May 10, 10:50 a.m. ET – Dr. Volkan Granit, Neurologist at the University of Miami Health System, will present clinical research of Cartesian’s first CAR T-cell therapy for the treatment of generalized myasthenia gravis (GMG). Descartes-08 contains autologous CD8+ T-cells engineered with RNA chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). BCMA is expressed ubiquitously by plasma cell clones that produce pathogenic autoantibodies. Descartes-08 binds and kills these cells, eliminating the autoantibody source.

May 10, 6:00 p.m. ET – Cartesian will present a poster on clinical research from its Phase 1a/2a study for Descartes-08 in patients with generalized Myasthenia Gravis. Patients were treated with increasing doses to determine the safety and preliminary efficacy.

January 25-28, 2022, Miami Beach Convention Center

Jan. 27, 2:05 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in a session titled “Delivery Solutions and Alternatives for Gene and Cell Therapy,” with a specific emphasis on RNA Cell Therapy in And Beyond Oncology.

Jan. 28, 11:05 a.m. ET – Dr. Emily English, Director of Quality, participates in a session titled “Achieving Best Practice in Quality Control and Assurance,” with a focus on providing an overview of our experience building and evolving quality management systems in an early-stage cell therapy company.

January 20, 2022

9:00 a.m. ET – Dr. Murat Kalayoglu joins John Stanford, Executive Director at Incubate, in a fireside chat titled “Protecting Innovation: Putting Patients First.” The Maryland Tech Council’s Advocacy Summit will bring industry leaders together to build meaningful relationships with elected officials, provide information about policies that can transform millions of lives and tips on how your advocacy with policymakers in Annapolis can make a difference.

October 22, 2021

Dr. Murat Kalayoglu is joined by other Montgomery County owners and developers, discussing how best to foster the lab space and talent in the area. The discussion focused on nurturing and leveraging the resources of Montgomery County to retain and expand the biotech industry, as well as other growth opportunities in the County.

October 5, 2021

9:00 a.m. – Dr. Michael Singer participates in a panel titled “Engineered Cell Therapies: Increasingly Complex Product Development.” In this panel, Dr. Singer will explore how Cartesian is developing innovative approaches for novel cell therapeutics for the treatment of a growing list of intractable diseases. The presentation will be followed by a short Q&A session with the panelists.

11:00 a.m. – Dr. Murat Kalayoglu moderates a panel titled “Cell and Gene Therapy: Beyond Oncology.” The panel discusses the applications of cell therapy beyond the treatment of advanced cancers. Specific examples include the use of cell & gene therapy for the treatment of autoimmune disorders such as myasthenia gravis, respiratory diseases such as ARDS and COVID-19, and rare genetic disorders such as XMEN disease. Ex-vivo cell modification strategies are compared between different approaches and disease indications. Potential benefits of these novel approaches are weighed against treatment risks and costs.

September 2, 2021

12:00 p.m. – Dr. Murat Kalayoglu provides a corporate presentation and participates in a Q&A session focused on deploying the company’s RNA Armory® platform to equip cell immunotherapies beyond oncology. He discusses the biological basis and cell therapy engineering approaches to combat respiratory and autoimmune disorders, shares experiences in developing a cGMP manufacturing facility in-house for RNA-based cell therapies, highlights the distinct advantages of an RNA-based engineering platform to targetcells to diseased tissues to deliver any combination of therapies, and provides updates on phase I/II clinical trials for investigational therapies in multiple myeloma, myasthenia gravis, and acute respiratory distress syndrome linked to COVID-19.

2:00 p.m. – Dr. Murat Kalayoglu participates in a panel reflecting on historic developments in the industry, and the ‘why’ behind CAR-TCR’s launch into oncology and discussing the relative advantages and challenges of expanding these technologies to indications beyond oncology.

May 20, 2021

Cartesian has been selected as a finalist of the “Emerging Life Sciences Company of the Year” and Dr. Murat Kalayoglu has been selected as a finalist for the “Chief Executive Officer of the Year – Life Sciences” by the Maryland Tech Council. The winners of the awards will be announced at the Industry Awards Celebration on May 20. The event celebrates individuals and companies in the government contracting, life sciences and technology industries that have made a significant impact in their respective industry.

March 24, 2021

In this panel, Dr. Metin Kurtoglu, Cartesian’s Chief Medical Officer, speaks to Cartesian’s expertise in manufacturing and characterizing the function and potency of CAR-T cell products using its wholly-owned, state-of-the-art GMP manufacturing facility.

March 2- March 5, 2021

Dr. Kelly Gwanthemey, Assistant Prof of Neurology at Virginia Commonwealth University, presents on emerging therapeutics in myasthenia gravis, including Cartesian’s work with an mRNA cell therapy, Descartes-08.

October 19, 2020

Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, participated in a panel titled, “Strengths of the Regions – Cutting Edge Therapies.” The panel brought together leaders from three companies to discuss their disruptive pipelines, the strength of the region and challenges brought by the COVID-19 pandemic.

September 16, 2020

Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, joins a panel hosted by Martin Rosendale, CEO of the Maryland Tech Council. On this CapitalM ZoomCast Live event Dr. Kalayoglu discusses Cartesian and its role in the Maryland science eco-system.

Scroll to Top